Front. Oncol.
Frontiers in Oncology
Front. Oncol.
2234-943X
Frontiers Media S.A.
10.3389/fonc.2022.1081632
Oncology
Correction
Corrigendum: CDKN2A determines mesothelioma cell fate to EZH2 inhibition
Pinton
Giulia
1
*
Wang
Zhuo
2
Balzano
Cecilia
1
Missaglia
Sara
3
Tavian
Daniela
3
Boldorini
Renzo
4
Fennell
Dean A.
5
Griffin
Martin
2
Moro
Laura
1
*
1
Department of Pharmaceutical Sciences, University of Piemonte Orientale (UPO), Novara, Italy
2
School of Life and Health Sciences, Aston University, Birmingham, United Kingdom
3
Laboratory of Cellular Biochemistry and Molecular Biology, Centro di Ricerca in Biochimica E Nutrizione dello Sport (CRIBENS), Catholic University of the Sacred Heart, Milan, Italy
4
Department of Health Science, University of Piemonte Orientale (UPO), Novara, Italy
5
Leicester Cancer Research Centre, University of Leicester, Leicester, United Kingdom
Approved by: Frontiers Editorial Office, Frontiers Media SA, Switzerland
*Correspondence: Laura Moro, laura.moro@uniupo.it; Giulia Pinton, giulia.pinton@uniupo.it
This article was submitted to Cancer Molecular Targets and Therapeutics, a section of the journal Frontiers in Oncology
23
11
2022
2022
12
1081632
27
10
2022
31
10
2022
Copyright © 2022 Pinton, Wang, Balzano, Missaglia, Tavian, Boldorini, Fennell, Griffin and Moro
2022
Pinton, Wang, Balzano, Missaglia, Tavian, Boldorini, Fennell, Griffin and Moro
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
A corrigendum on CDKN2A determines mesothelioma cell fate to EZH2 inhibition by Pinton G, Wang Z, Balzano C, Missaglia S, Tavian D, Boldorini R, Fennell DA, Griffin M and Moro L (2021). Front. Oncol. 11:678447. doi: 10.3389/fonc.2021.678447
malignant pleural mesothelioma
EZH2 inhibitor
CDKN2A/p16ink4a
TG2
multicellular spheroids
In the original article, there was an error in the Funding statement as published. The correct funding statement is “The authors acknowledge the financial support of project HERMES (HEreditary Risk in MESothelioma) and Università del Piemonte Orientale (Bando ricerca locale 2019)”.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.